Trials / Completed
CompletedNCT04306484
18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 74 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Background: 3,4-dihydroxy-6-\[18F\]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) can identify well low and high grade brain tumors. However, increased FDOPA uptake has been reported in non-tumoral brain lesions. The aim was to analyse FDOPA-PET in patients with non-tumoral brain lesions and to compare them with patients with (low and high grade) brain tumors. Methods: retrospective analyse. Patients consecutively recruited with suspected primary brain tumor (based on clinical and MRI findings) referred for FDOPA-PET at Nimes university Hospital between June 2015 and June 2019. FDOPA-PET parameters (maximum and mean lesion standardized uptake values \[SUV\] and ratios comparing lesion with different background uptake SUV) and thresholds were analysed in search for those offering optimal discrimination between non-tumoral and tumoral lesions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | FDOPA-TEP | FDOPA-TEP performed as part of the normal management of a suspected brain tumour |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2020-03-13
- Last updated
- 2025-12-04
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04306484. Inclusion in this directory is not an endorsement.